Patents Assigned to Universite de Versailles St-Quentin En Yvelines
-
Publication number: 20230134548Abstract: The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.Type: ApplicationFiled: July 15, 2022Publication date: May 4, 2023Applicants: UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: François GIULIANO, Alberto EPSTEIN, Olivier LE COZ, Alejandro ARANDA
-
Patent number: 11414666Abstract: The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.Type: GrantFiled: June 23, 2017Date of Patent: August 16, 2022Assignees: UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: François Giuliano, Alberto Epstein, Olivier Le Coz, Alejandro Aranda
-
Publication number: 20220042016Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: September 29, 2021Publication date: February 10, 2022Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUDInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Patent number: 11162100Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: January 6, 2020Date of Patent: November 2, 2021Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, UNIVERSITE PARIS-SUDInventors: William Vainchenker, Valerie Ugo, Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20200140863Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: January 6, 2020Publication date: May 7, 2020Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris - SUDInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Publication number: 20200071703Abstract: The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.Type: ApplicationFiled: June 23, 2017Publication date: March 5, 2020Applicants: UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARISInventors: François GIULIANO, Alberto EPSTEIN, Olivier LE COZ, Alejandro ARANDA
-
Publication number: 20190392612Abstract: The invention relates to a process for determining an infiltration profile of biological cells of interest in a biological object of interest from a digital histopathological image of biological tissues, a histological stain having previously been applied to the biological tissues, comprising generating a biological cell detection image, pixels associated with the histological stain on the histopathological image being of a predetermined color on said image, determining a distance map comprising distance iso-curves to the boundary of the biological object, and, from the distance map, calculating a curve representative of the surface density of biological cells of interest as a function of distance to the boundary, by counting, for each boundary distance value, pixels that are both of the predetermined color on the detection image and located between the iso-curve associated with said distance value and the consecutive iso-curve.Type: ApplicationFiled: June 4, 2019Publication date: December 26, 2019Applicants: Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Ecole Nationale Superieure de Chimie de Paris, Assistance Publique-Hopitaux de Paris, Universite De Versailles-St Quentin En Yvelines, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Kathia Lemdani, Johanne Seguin, Armand Tiede Djiro, Jean-Francois Emile, Camille Kurtz, Nicolas Lomenie
-
Publication number: 20190323007Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: May 29, 2019Publication date: October 24, 2019Applicants: Institut Gustave-Roussy, Institut National de la Sante et de la Rescherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite de Versailles - St Quentin en Yvelines, Universite Paris-SudInventors: William VAINCHENKER, Valerie UGO, Chloe James, Jean-Pierre LE COUEDIC, Nicole CASADEVALL
-
Publication number: 20190201492Abstract: The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.Type: ApplicationFiled: August 31, 2017Publication date: July 4, 2019Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Ecole Nationale Superieure de Chimie de Paris, Universite de Versailles-St Quentin en YvelinesInventors: Robert Malafosse, Nathalie Mignet, Vincent Boudy, Johanne Seguin, Kathia Lemdani, Claude Capron
-
Publication number: 20140249204Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: January 27, 2014Publication date: September 4, 2014Applicants: Institut Gustave-Roussy, Institut National De La Sante Et De La Rechereche Scientifique (Inserm), Universite Paris-Sud, Universite De Versailles - St Quentin En Yvelines, Assistance Publique-Hopitaux De ParisInventors: William Vainchenker, Valeria Ugo, James Chloe, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20130189683Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: February 15, 2013Publication date: July 25, 2013Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, IGR&D SA, UNIVERSITE PARIS-SUD, INSTITUT GUSTAVE-ROUSSY, UNIVERSITE DE VERSAILLES - ST QUENTIN EN YVELINES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Assistance Publique - Hopitaux De Paris, IGR&D SA, Institut National De La Sante Et De La Recherche Medicale (INSERM), Institut Gustave-Roussy, Universite De Versailles - St Quentin En Yvelines, Universite Paris-Sud
-
Publication number: 20130164762Abstract: The present invention relates to a method for the prognosis of the progression of a solid tumour in a patient, which includes at least the following steps: a) making, from a tumour sample, a virtual slide on which a tumour front can be identified; b) quantifying, on said virtual slide made in step a), the density of cells and/or blood vessels present in a continuous area covering the tumour front and extending on either side of the tumour front over a distance of at least 0.5 mm, referred to as the quantification area; and c) deducing, from said quantification, the risks of postoperative relapse and/or the sensitivity to various antitumor treatments and/or the risks of developing metastases in said patient. Preferably, the cells to be quantified are leukocytes, such as T cells, B cells, macrophages, natural killer cells, dendritic cells, or subpopulations of these immune system cells.Type: ApplicationFiled: September 9, 2011Publication date: June 27, 2013Applicants: Assistance Publique-Hopitaux De, Universite de Versailles-ST Quentin en YvelinesInventors: Jean-Francois Emile, Marc-Antoine Allard
-
Patent number: 8471453Abstract: The disclosure relates to a Hall-effect ion ejection device that comprises a longitudinal axis substantially parallel to the ion ejection direction, and comprises at least: a main ionization and acceleration annular channel, the annular channel being open at its end; an anode extending inside the channel; a cathode extending outside the channel at the outlet thereof; a magnetic circuit for generating a magnetic field in a portion of the annular channel, said circuit including at least an annular inner wall, an annular outer wall and a bottom connecting the inner and outer annular walls and defining the downstream portion of the magnetic circuit; characterized in that the magnetic circuit is arranged so as to create at the outlet of the annular channel a magnetic field independent from the azimuth.Type: GrantFiled: August 4, 2008Date of Patent: June 25, 2013Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Versailles St Quentin en Yvelines, Centre National d'Etudes SpatialesInventors: Marcel Guyot, Patrice Renaudin, Vladimir Cagan, Claude Boniface
-
Patent number: 8466338Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: GrantFiled: August 19, 2011Date of Patent: June 18, 2013Assignees: Assistance Publique-Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave-Roussy, Universite de Versailles-St Quentin en Yvelines, Universite Paris-SudInventors: William Vainchenker, Valérie Ugo, James Chloé, Jean-Pierre Le Couedic, Nicole Casadevall
-
Publication number: 20100244657Abstract: The disclosure relates to a Hall-effect ion ejection device that comprises a longitudinal axis substantially parallel to the ion ejection direction, and comprises at least: a main ionization and acceleration annular channel, the annular channel being open at its end; an anode extending inside the channel; a cathode extending outside the channel at the outlet thereof; a magnetic circuit for generating a magnetic field in a portion of the annular channel, said circuit including at least an annular inner wall, an annular outer wall and a bottom connecting the inner and outer annular walls and defining the downstream portion of the magnetic circuit; characterised in that the magnetic circuit is arranged so as to create at the outlet of the annular channel a magnetic field independent from the azimuth.Type: ApplicationFiled: August 4, 2008Publication date: September 30, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS, UNIVERSITE DE VERSAILLES ST QUENTIN EN YVELINES, CENTRE NATIONAL D'ETUDES SPATIALESInventors: Marcel Guyot, Patrice Renaudin, Vladimir Cagan, Claude Boniface
-
Patent number: 7368317Abstract: The invention relates to a method of producing an n-type diamond. The inventive method comprises an n-doping stage during which a donor species is vacuum diffused in a diamond that was initially doped with an acceptor, in order to form donor groups containing the donor species, at a temperature that is less than or equal to the dissociation temperature of the complexes formed between the acceptor and the donor species.Type: GrantFiled: June 3, 2005Date of Patent: May 6, 2008Assignees: Centre National de la Recherche Scientifique-CNRS, Universite de Versailles St-Quentin En YvelinesInventors: Jacques Paul Marie Chevallier, Zephirin Symplice Teukam, Dominique Ballutaud
-
Publication number: 20050266606Abstract: The invention relates to a method of producing an n-type diamond. The inventive method comprises an n-doping stage during which a donor species is vacuum diffused in a diamond that was initially doped with an acceptor, in order to form donor groups containing the donor species, at a temperature that is less than or equal to the dissociation temperature of the complexes formed between the acceptor and the donor species.Type: ApplicationFiled: June 3, 2005Publication date: December 1, 2005Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE-CNRS, UNIVERSITE DE VERSAILLES ST-QUENTIN EN YVELINESInventors: Jacques Chevallier, Zephirin Teukam, Dominique Ballutaud